GlaxoSmithKline plc says it has received US approval to sell its once-a-day respiratory inhaler Breo Ellipta for a new use in asthma patients ages 18 and older.
The expanded approval from the Food and Drug Administration will help Glaxo replace sales of its best-selling product, Advair, which faces generic competition in Europe and pricing pressures in the US.
Breo Ellipta was originally approved to treat a form of lung disease. But Thursday’s approval expands the drug’s use to a much larger patient population of roughly 19 million US adults who have asthma. The inhalable formulation combines two drug ingredients that help open the lung airways: a steroid and a beta agonist.
London-based Glaxo pays royalties on Breo Ellipta to the drug’s co-developer Theravance Inc., which is based in San Francisco.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.